Prostate Cell News Volume 8.19 | May 26 2017

TOP STORY

Preclinical Study Using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9^® to Suppress Enzalutamide-Resistant Prostate Cancer Progression

Scientists established enzalutamide resistant-prostate cancer cell lines and examined the long noncoding RNA Malat1 (Malat1) function in conferring enzalutamide resistance. They also examined the in vivo effects of Malat1 short interfering RNA and the AR-v7 degradation enhancer, ASC-J9^®. [Eur Urol] Full Article

(Ranked by impact factor of the journal)

LABORATORY RESEARCH

Androgen Receptor Inhibitor–Induced “BRCAness” and PARP Inhibition Are Synthetically Lethal for Castration-Resistant Prostate Cancer

Researchers found that castration-resistant prostate cancer cells showed increased expression of a set of homologous recombination-associated genes, including BRCA1, RAD54L, and RMI2. [Sci Signal] Abstract

Niclosamide and Bicalutamide Combination Treatment Overcomes Enzalutamide and Bicalutamide Resistant Prostate Cancer

To determine whether androgen receptor (AR) variants play a role in bicalutamide resistance, scientists developed bicalutamide resistant LNCaP cells and found that these resistant cells express significantly increased levels of AR variants, particularly AR-V7, both at the mRNA and protein levels. [Mol Cancer Ther] Abstract

TLR9 Expression and Secretion of LIF by Prostate Cancer Cells Stimulates Accumulation and Activity of Polymorphonuclear MDSCs

The authors investigated whether cancer cell–intrinsic TLR9 signaling alters composition of the prostate tumor microenvironment. They generated Ras/Myc and Myc-driven prostate cancer cells expressing the tetracycline-inducible gene Tlr9 or the control LacZ. [J Leukoc Biol] Abstract

Identification of Endonuclease Domain-Containing 1 as a Novel Tumor Suppressor in Prostate Cancer

Scientists investigated the role of endonuclease domain containing 1 (ENDOD1) in prostate cancer (PCa). Real-time PCR and western blot were used to detect ENDOD1 mRNA and protein expression in normal prostatic epithelial and PCa cell lines. [BMC Cancer] Full Article

Inhibition of Autophagy Promotes Salinomycin-Induced Apoptosis via Reactive Oxygen Species-Mediated PI3K/AKT/mTOR and ERK/p38 MAPK-Dependent Signaling in Human Prostate Cancer Cells

Investigators assessed whether salinomycin, a promising anticancer drug, induces apoptosis and elucidated potential antitumor mechanisms in chemo-resistant prostate cancer cells. [Int J Mol Sci] Full Article

Dual Strands of Pre-miR-150 (miR-150-5p and miR-150-3p) Act as Antitumor miRNAs Targeting SPOCK1 in Naïve and Castration-Resistant Prostate Cancer

The authors investigated the functional significance of miR-150-5p and miR-150-3p in naïve prostate cancer and castration-resistant prostate cancer. [Int J Oncol] Abstract

Nintedanib Antiangiogenic Inhibitor Effectiveness in Delaying Adenocarcinoma Progression in Transgenic Adenocarcinoma of the Mouse Prostate (TRAMP)

Investigators evaluated the effectiveness of nintedanib treatment against in vitro proliferation of human prostate cancer (PCa) cell lines, and growth and progression of different grades of PCa lesions in pre-clinical PCa TRAMP model. [J Biomed Sci] Full Article

CLINICAL RESEARCH

Phase I Clinical Trial of Cell Division Associated 1 (CDCA1) Peptide Vaccination for Castration Resistant Prostate Cancer

Researchers conducted a Phase I clinical trial for patients with castration resistant prostate cancer (CRPC) using a CDCA1 peptide vaccination. Twelve patients having HLA-A*2402 with CRPC after failure of docetaxel chemotherapy were enrolled. [Cancer Sci] Abstract

Magnetic Nanoformulations for Prostate Cancer

The authors provide significant insight and advances in the theranostic role of magnetic nanoparticles through the documentation of unique magnetic nanoparticles used in prostate cancer, their interaction with prostate cancer cells, in vivo fate, targeting, and biodistribution. [Drug Discov Today] Abstract

Visit our reviews page to see a complete list of reviews in the prostate cell research field.

Sophiris Bio Provides Update on Phase IIb Study of Topsalysin in Localized Prostate Cancer

Sophiris Bio Inc. reported that it has received the regulatory clearance for the diluent – the medium in which topsalysin is diluted. Clinical sites can now begin dosing eligible patients in a Phase IIb study in localized prostate cancer. [Sophiris Bio Inc.] Press Release

Churchill Pharmaceuticals Announces Submission of NDA for Novel Oral Formulation of Prostate Cancer Treatment

Churchill Pharmaceuticals, LLC., announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration for YONSA™, an improved ultramicrosize formulation of abiraterone acetate. YONSA is a CYP17 inhibitor for the treatment of metastatic castration-resistant prostate cancer in combination with methylprednisolone. [Churchill Pharmaceuticals, LLC.] Press Release

ORYX Reports Positive Clinical Evidence with Oncolytic Virus ParvOryx in Combination with Immuno-Oncology Drugs

ORYX announced positive findings from 16 patients treated with the oncolytic virus, ParvOryx, in combination with Avastin^® and with immune checkpoint inhibitors Keytruda^® or Opdivo^® under compassionate use programs. [ORYX] Press Release

How NSF Cut 11% from Its Budget

Donald Trump planned to include an 11% cut to National Science Foundation’s (NSF)’s $7.4 billion budget in his first full spending request to Congress. The news—which was publicly unveiled as part of the president’s $4.1 trillion budget for 2018—sent Jim Olds, who leads the biology directorate at the NSF, and the heads of NSF’s other six research and education programs scrambling to erase big chunks of their portfolios without sacrificing NSF’s ability to fund the best new ideas. [ScienceInsider] Editorial

Colombian Biologist Cleared of Criminal Charges for Posting Another Scientist’s Thesis Online

A Colombian biologist who faced a criminal trial for posting another scientist’s thesis online has been cleared of copyright violation — an offense that, under Colombian law, might have brought him a jail sentence. [Nature News] Editorial

Tissue-Independent Cancer Drug Gets Fast-Track Approval from US Regulator

The US Food and Drug Administration has issued its first approval of a cancer drug that targets tumors with specific mutations, regardless of where in the body the tumor first took root. [Nature News] Editorial

China Expands DNA Data Grab in Troubled Western Region

Police in the northwestern region of Xinjiang, China, have been collecting DNA samples from citizens and are now ramping up their capacity to analyze that genetic cache, according to evidence compiled by activists and details gathered by Nature. [Nature News] Editorial

NEW AACR-NCI-EORTC Molecular Targets & Cancer Therapeutics
October 26-30, 2017
Philadelphia, United States

Visit our events page to see a complete list of events in the community.

NEW Research Associate – Prostate Cancer (Meharry Medical College)

Assistant Professor – Prostate Cancer, Carcinogenesis and Chemoprevention, Advanced Tissue Imaging (University of Illinois at Chicago)

Pathology Clinical Research Fellow – Treatment of Men with Advanced Prostate Cancer (Institute of Cancer Research)

Postdoctoral Fellow – Androgen Action in Prostate Cancer (Lerner Research Institute, Cleveland Clinic)

Postdoctoral Senior Fellow – Microbiology, Genetics, and Translational Prostate Cancer Research (University of Washington)

Postdoctoral Fellow – Mammalian Stem Cell Biology (NYU School of Medicine)

Postdoctoral Fellow – Translational Prostate Cancer Research (Weill Cornell Medicine)

Postdoctoral Fellow Positions – Gene Regulation in Cancer Progression (University of Texas Health Science Center at San Antonio)

Postdoctoral Fellow – Prostate Cancer (University of South Carolina-School of Medicine)

Faculty Position – Genitourinary Oncology (Northwestern University)

Postdoctoral Fellow – Cancer Biology (Northwestern University)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here.